Prostate cancer, andogen deprivation, bone density Prostaatkanker, androgeen deprivatie, botdichtheid
Conditions
Interventions
By measuring BMD by two different methods, the change in BMD estimated bye ach method will be compared
Sponsors
SFG, Rotterdam, The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: Age >18 years 1. Indication for ADT as treatment for nonmetastatic prostate cancer according to the Bolla schedule; 2. Planned ADT or recently started ADT (max 4 weeks before baseline DEXA measurement); 3. Signed informed consent.
Exclusion criteria
Exclusion criteria: Pre-existing indication for osteoporosis treatment, i.e. before the baseline DEXA scan. 1. Current or prior treatment with bisphosphonates and/or RANK ligand inhibitors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Agreement between the change in Achilles T-scores and the change in DEXA scan T-scores. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of repeated delta T-scores over time of the DEXA and Achilles scans • Association between (absolute) Achilles T-scores and (absolute) DEXA T-scores at each available time point. | — |
Contacts
Public ContactA.P. Hamberg
PO Box 5201
Outcome results
None listed